Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1400362
European Journal of Endocrinology, Vol 140, Issue 4, 362-366
Copyright © 1999 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vuaroqueaux, V
Right arrow Articles by Ouafik, L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vuaroqueaux, V
Right arrow Articles by Ouafik, L
Articles

No loss of sst receptors gene expression in advanced stages of colorectal cancer

V Vuaroqueaux, A Dutour, N Briard, G Monges, M Grino, C Oliver, and L Ouafik

Laboratoire des Interactions Fonctionnelles en Neuroendocrinologie, INSERM U 501, Institut Jean-Roche, UER de Medecine secteur Nord, Bvd Pierre Dramard, 13916 Marseille Cedex 20, France.

As demonstrated by several studies, the pan-inhibitory peptide somatostatin (SS) is implicated in a large variety of physiological processes in the gastrointestinal tractus. SS inhibits hormonal and gastric acid secretions, and decreases gastric and intestinal motility, mesenteric blood flow and intestinal absorption. In vitro and in vivo studies showed also that the antiproliferative potency of SS analogs may be a target to improve the prognosis of colorectal cancer. Here we report the expression profile of the five SS receptor subtypes (hsst1-5) mRNAs in a large set of tumoral and normal colon. Using reverse transcription-PCR, we showed that hsst5, hsst1 and hsst2 mRNA subtypes were the most frequently expressed hsst mRNA subtypes in normal and pathological colon. Interestingly, we found that the frequency of hsst5 mRNA expression in the left colon was significantly higher in tumors than in normal samples: 81. 2% (13/16) and 36.4% (4/11) respectively (0.025>P>0.01, chi2 test with Yates' correction). We did not find any influence of Dukes' stage on hsst mRNAs expression. Of interest, no loss of hsst2 and hsst5 mRNA expression in advanced stages was noted. Some differences in the frequency of expression of hsst mRNAs according to the origin of the tissue (left or right colon) were evident. The expression of hsst5 and hsst2 mRNA in advanced colorectal carcinoma associated with the development of new SS analogs boost the relevance of colorectal cancer treatment by somatostatin analogs.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
K. Szepeshazi, A. V. Schally, G. Halmos, P. Armatis, F. Hebert, B. Sun, A. Feil, H. Kiaris, and A. Nagy
Targeted Cytotoxic Somatostatin Analogue AN-238 Inhibits Somatostatin Receptor-positive Experimental Colon Cancers Independently of Their p53 Status
Cancer Res., February 1, 2002; 62(3): 781 - 788.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. C. Raggi, A. Calabro, D. Renzi, V. Briganti, F. Cianchi, L. Messerini, R. Valanzano, M. C. Smith, C. Cortesini, F. Tonelli, et al.
Quantitative Evaluation of Somatostatin Receptor Subtype 2 Expression in Sporadic Colorectal Tumor and in the Corresponding Normal Mucosa
Clin. Cancer Res., February 1, 2002; 8(2): 419 - 427.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 European Society of Endocrinology.